Recent Advances in Antiarrhythmic Drug Therapy

Research output: Contribution to journal › Review › Research › peer-review

Standard

Recent Advances in Antiarrhythmic Drug Therapy. / Saljic, Arnela; Heijman, Jordi; Dobrev, Dobromir.

In: Drugs, Vol. 83, No. 13, 2023, p. 1147 - 1160.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Saljic, A, Heijman, J & Dobrev, D 2023, 'Recent Advances in Antiarrhythmic Drug Therapy', Drugs, vol. 83, no. 13, pp. 1147 - 1160. https://doi.org/10.1007/s40265-023-01923-3

APA

Saljic, A., Heijman, J., & Dobrev, D. (2023). Recent Advances in Antiarrhythmic Drug Therapy. Drugs, 83(13), 1147 - 1160. https://doi.org/10.1007/s40265-023-01923-3

Vancouver

Saljic A, Heijman J, Dobrev D. Recent Advances in Antiarrhythmic Drug Therapy. Drugs. 2023;83(13):1147 - 1160. https://doi.org/10.1007/s40265-023-01923-3

Author

Saljic, Arnela ; Heijman, Jordi ; Dobrev, Dobromir. / Recent Advances in Antiarrhythmic Drug Therapy. In: Drugs. 2023 ; Vol. 83, No. 13. pp. 1147 - 1160.

Bibtex

@article{03269a8dce864f6f9dfe1d75ec8cc7ec,
title = "Recent Advances in Antiarrhythmic Drug Therapy",
abstract = "Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse proarrhythmic effects. Due to conceptual, regulatory and financial considerations, the number of novel antiarrhythmic targets and agents in the development pipeline has decreased substantially during the last few decades. However, several promising candidates remain and there are exciting developments in repurposing and reformulating already existing drugs for indications related to cardiac arrhythmias. This review discusses the key conceptual considerations for the development of new antiarrhythmic agents, summarizes new compounds and formulations currently in clinical development for rhythm control of atrial fibrillation, and highlights the potential for drug repurposing. Finally, future directions in AAD development are discussed. Together with an ever-increasing understanding of the molecular mechanisms underlying cardiac arrhythmias, these components support a cautiously optimistic outlook towards improved pharmacological treatment opportunities for patients suffering from cardiac arrhythmias.",
author = "Arnela Saljic and Jordi Heijman and Dobromir Dobrev",
note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
doi = "10.1007/s40265-023-01923-3",
language = "English",
volume = "83",
pages = "1147 -- 1160",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "13",

}

RIS

TY - JOUR

T1 - Recent Advances in Antiarrhythmic Drug Therapy

AU - Saljic, Arnela

AU - Heijman, Jordi

AU - Dobrev, Dobromir

N1 - Publisher Copyright: © 2023, The Author(s).

PY - 2023

Y1 - 2023

N2 - Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse proarrhythmic effects. Due to conceptual, regulatory and financial considerations, the number of novel antiarrhythmic targets and agents in the development pipeline has decreased substantially during the last few decades. However, several promising candidates remain and there are exciting developments in repurposing and reformulating already existing drugs for indications related to cardiac arrhythmias. This review discusses the key conceptual considerations for the development of new antiarrhythmic agents, summarizes new compounds and formulations currently in clinical development for rhythm control of atrial fibrillation, and highlights the potential for drug repurposing. Finally, future directions in AAD development are discussed. Together with an ever-increasing understanding of the molecular mechanisms underlying cardiac arrhythmias, these components support a cautiously optimistic outlook towards improved pharmacological treatment opportunities for patients suffering from cardiac arrhythmias.

AB - Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse proarrhythmic effects. Due to conceptual, regulatory and financial considerations, the number of novel antiarrhythmic targets and agents in the development pipeline has decreased substantially during the last few decades. However, several promising candidates remain and there are exciting developments in repurposing and reformulating already existing drugs for indications related to cardiac arrhythmias. This review discusses the key conceptual considerations for the development of new antiarrhythmic agents, summarizes new compounds and formulations currently in clinical development for rhythm control of atrial fibrillation, and highlights the potential for drug repurposing. Finally, future directions in AAD development are discussed. Together with an ever-increasing understanding of the molecular mechanisms underlying cardiac arrhythmias, these components support a cautiously optimistic outlook towards improved pharmacological treatment opportunities for patients suffering from cardiac arrhythmias.

U2 - 10.1007/s40265-023-01923-3

DO - 10.1007/s40265-023-01923-3

M3 - Review

C2 - 37540446

AN - SCOPUS:85166930633

VL - 83

SP - 1147

EP - 1160

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 13

ER -

ID: 362696341